Who Paid My Doc Search
Menu
Organisation paid for research Program year 2023 Source: CMS Open Payments

Viable Research Management

Neither a doctor nor a teaching hospital

Research payments

$675,151

78 payments

Through program year 2023, Viable Research Management is reported as receiving $675,151 in research payments, across 78 payments.

By program year

5 rows
Year Kind Amount Payments
2023 Research $11,429 4
2022 Research $43,141 8
2021 Research $414,465 39
2020 Research $78,293 15
2019 Research $127,823 12

Breakdown

Who paid Research payments · program years 2019–2023
  1. Pfizer Inc. $427,425 35 payments
  2. AbbVie, Inc. $223,199 35 payments
  3. Kadmon Corporation LLC $13,720 2 payments
  4. Sanofi US Services Inc. $5,500 3 payments
  5. Janssen Research & Development, LLC $5,307 3 payments
Studies the money was for Research payments · program years 2019–2023
  1. A Phase 2B Randomized Doubleblind Placebocontrolled Parallel Group Doseranging Study to Assess the Efficacy Safety and Tolerability of Vupanorsen Pf07285557 in Statintreated Participants With Dyslipidemia $366,465 22 payments
  2. M16-100 $163,330 19 payments
  3. A 16Week Phase 2B Randomized Doubleblind Placebocontrolled Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Pf06882961 Administration in Adults With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Or Diet and Exercise $37,009 8 payments
  4. A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men $31,908 7 payments
  5. Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study $27,960 9 payments
  6. A Phase 2 Randomized Placebo controlled Doubleblind Openlabel Extension Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects with Diffuse Cutaneous Systemic Sclerosis $13,720 2 payments
  7. A 16Week Phase 2 Randomized Doubleblind Placebocontrolled Parallel Group Study to Evaluate the Efficacy and Safety of Once Daily Pf06882961 Administration in Adults With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin $12,895 3 payments
  8. A Phase 23 Twopart Study to Evaluate the Efficacy and Longterm Safety With Oral Etrasimod 2 MG Once Daily in Adult Participants With Moderatetosevere Atopic Dermatitis With A History of Prior Systemic Treatment Failure $11,056 2 payments
  9. Observational Evaluation of Atopic Dermatitis in Pediatric Patients (PEDISTAD) $5,500 3 payments
  10. A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (=10 to <18 Years) With Type 2 Diabetes Mellitus $2,592 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record